-+ 0.00%
-+ 0.00%
-+ 0.00%

Rani Therapeutics Initiated Phase 1 Trial of RT-114, an Orally Administered Ranipill Capsule Containing GLP-1/GLP-2 Dual Agonist, PG-102, for Obesity

Benzinga·01/08/2026 12:14:55
Listen to the news
  • PG-102 is a fc-fusion protein conjugated GLP-1/GLP-2 dual agonist in development by ProGen Co., Ltd. ("ProGen"). ProGen recently announced preclinical and clinical data, at the 2025 European Association for the Study of Diabetes (EASD) meeting, demonstrating glucose-lowering effects and meaningful early weight-loss signals by PG-102, reinforcing its potential as a next-generation metabolic therapy.
  • In preclinical testing of RT-114 in animal models, the RaniPill® delivered PG-102 orally with bioavailability, pharmacokinetics, and weight loss comparable to subcutaneous (SC) injection.